Advertisement

Histopathological Effect of Preoperative Chemotherapy Using Oral 5-Fluorouracil in Patients with Operable Gastric Cancer

  • Masashi Fujii
  • Goro Kosaki
  • Shuji Tsuchiya
  • Kozaburo Kimura
  • Hiroyoshi Suzuki
  • Toshifusa Nakajima
  • Yasuyuki Awane
  • Masatsugu Kitamura
  • Yoichi Kitamura
  • Kazunobu Suzuki
  • Shigeru Tsurui
  • Kiyoshi Nishiyama
  • Jun-ichi Wakasugi
  • Mitsugu Kochi
  • Mitsuyoshi Nakashima
  • Gastric Cancer Chemotherapy Group

Abstract

Recent studies of modulated 5-fluorouracil (5-FU) have reported a high response rate in patients with metastatic and advanced gastric and colorectal cancer [1]. 5-FU tablets (Kyowa Hakko, Japan) have been commercially available in Japan since the 1970s and are widely used for the treatment of gastric, colorectal, and breast cancer. The drug is mainly employed in an adjuvant setting with long-term oral administration in mild toxic dose schedules [2]. However, there has been no marked benefit of postoperative adjuvant chemotherapy for 5-year survival, except in the stage II or III subgroups of gastric carcinoma [3,4].

Keywords

Gastric Cancer Histological Grade Gastric Cancer Patient Preoperative Chemotherapy Viable Tumor Cell 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Machover D, Goldcshmidt E, Chollet P, Metzger G, Zittoun J, Marquet J, et al (1986) Treatment of advanced colorectal and gastric adenocarcinoma with 5-fluorouracil and high-dose folinic acid. J Clin Oncol 4:685–696PubMedGoogle Scholar
  2. 2.
    Fujii M, Sakabe T, Wakabayashi K, Kochi M, Mochizuki F, Kasakura Y, et al (1994) The optimal period for orally administered fluoropyrimidines as an adjuvant chemotherapy for gastric cancer. Jpn J Cancer Chemother 21:1199–1208Google Scholar
  3. 3.
    Hermans J, Bonenkamp JJ, Boon MC, Bunt MG, Ohyama S, Sasako M, et al (1993) Adjuvant therapy curative resection for gastric cancer: meta-analysis of randomized trial. J Clin Oncol 11:1441–1447PubMedGoogle Scholar
  4. 4.
    Hermans J, Bonenkamp JJ (1994) Meta-analysis of adjuvant chemotherapy in gastric cancer: in reply. J Clin Oncol 12:879–880Google Scholar
  5. 5.
    Japanese Reserch Society for Gastric Cancer (1995) Japanese classification of gastric carcinoma: histological criteria. Kanehara, Tokyo, pp 101–104Google Scholar
  6. 6.
    Nakajima T, Ota K, Ishihara S, Nishi M, Ohashi Y, et al (1997) Combined intensive chemotherapy and radical surgery for incurable gastric cancer. Ann Surg Oncol 4:203–208PubMedCrossRefGoogle Scholar
  7. 7.
    Mosmann T (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65:55–63PubMedCrossRefGoogle Scholar
  8. 8.
    Salmon S, Hamburger A, Soehnlen B, Durie BGM, Alberts DS, Moon TE, et al (1978) Quantitation of differential sensitivity of human-tumor stem cells to anticancer drugs. N Engl J Med 298:1321–1327PubMedCrossRefGoogle Scholar

Copyright information

© Springer Japan 1999

Authors and Affiliations

  • Masashi Fujii
    • 1
  • Goro Kosaki
    • 1
  • Shuji Tsuchiya
    • 1
  • Kozaburo Kimura
    • 1
  • Hiroyoshi Suzuki
    • 1
  • Toshifusa Nakajima
    • 1
  • Yasuyuki Awane
    • 1
  • Masatsugu Kitamura
    • 1
  • Yoichi Kitamura
    • 1
  • Kazunobu Suzuki
    • 1
  • Shigeru Tsurui
    • 1
  • Kiyoshi Nishiyama
    • 1
  • Jun-ichi Wakasugi
    • 1
  • Mitsugu Kochi
    • 1
  • Mitsuyoshi Nakashima
    • 1
  • Gastric Cancer Chemotherapy Group
  1. 1.Third Department of SurgeryNihon University School of MedicineTokyoJapan

Personalised recommendations